OXiGENE Announces Presentation of Data From the Phase 2 GOG186I Study at the 15th Biennial Meeting of the International Gynecologic Cancer Society

OXiGENE, Inc.

, a biopharmaceutical company developing novel cancer therapeutics, today announced that the data from the Phase 2 GOG186I study of fosbretabulin in combination with bevacizumab will be presented on Sunday, November 9 at the 15th Biennial Meeting of the International Gynecologic Cancer Society (IGCS) meeting being held in Melbourne, Australia. The study results will be presented in an oral presentation titled "Randomized Phase 2 Evaluation of Bevacizumab versus Bevacizumab/Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: A Gynecologic Oncology Group Study." A summary abstract regarding the study is currently available on the IGCS website at www2.kenes.com/igcs under "scientific programme" in the Scientific Information section. Additional data are expected to be included in the conference presentation on November 9, and the company will report on the additional data at that time.